Summit Therapeutics reported that the FDA issued a Complete Response Letter for its ivonescimab BLA in EGFR-mutated NSCLC, citing lack of statistically significant overall survival benefit despite a ...
Source LinkSummit Therapeutics reported that the FDA issued a Complete Response Letter for its ivonescimab BLA in EGFR-mutated NSCLC, citing lack of statistically significant overall survival benefit despite a ...
Source Link
Comments